SequelSEC

Pluri Inc. PLUR

Biological Products, (No Diagnostic Substances) · CIK 0001158780 · Fiscal year ends 0630

Revenue
$1.02M
Fiscal year ended 2026-06-30
Operating income
-$24.94M
Fiscal year ended 2026-06-30
Free cash flow
-$20.22M
Fiscal year ended 2026-06-30

Pluri Inc. (PLUR) reported revenue of $1.02M and net income of -$23.82M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Pluri Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Pluri Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.02M
Cost of revenue$563.00K
Gross profit$453.00K
Operating income-$24.94M
Net income-$23.82M
Research & development$15.09M
Weighted-average diluted sharesUnavailable
Pretax income-$25.39M
Income tax expense-$25.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$10.30M
Selling & marketingUnavailable

Balance

Pluri Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$3.53M
Total assets$24.88M
Current assets$8.73M
Total liabilitiesUnavailable
Current liabilities$32.72M
Total equity incl. NCI-$17.43M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$3.14M
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Pluri Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$19.59M
Capital expenditures$633.00K
Investing cash flow$9.90M
Financing cash flowUnavailable
Net change in cash-$2.62M
Stock-based compensation$3.73M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$511.00K

Derived

Pluri Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$20.22M
Gross margin44.6%
Operating margin-2454.5%
FCF margin-1990.3%
SBC / revenue366.7%
Current ratio0.27x
Revenue YoY growth-24.0%
Net margin-2344.6%
R&D / revenue1485.4%
CapEx / revenue62.3%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PLUR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-09-10View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-Q · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-K · Filed 2025-09-17View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.